-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Gain Therapeutics, Maintains $6 Price Target

Benzinga·03/28/2025 12:40:45
Listen to the news
Chardan Capital analyst Keay Nakae maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.